PharmAla Biotech is a Canadian biotechnology company dedicated to the domestic research & development and sourcing of clinical-grade LaNeo™ MDMA and novel MDXX compounds in service to the scientific research community.
Stock Performance
PharmAla Biotech News 76 articles
- PharmAla positions its GMP MDMA to supply new U.S. expanded-access pathway
- PharmAla signs MDMA supply-and-data deal with Nautilus Sanctuary for U.S. first-responder PTSD trial
- PharmAla to supply Amsterdam UMC with LaNeo MDMA and develop single-capsule stability data
- PharmAla files U.S. registration statement with the SEC
- PharmAla completes release testing on first Australian-made LaNeo MDMA capsules
- PharmAla Issues Q2 Financial Statements
- PharmAla Contracts with Partner to Act as US Distributor
- PharmAla Completes Shipment of LaNeo™ MDMA to the University of Washington
- PharmAla Signs Duchefa Farma as Exclusive Distributor in Netherlands
- PharmAla Completes Shipment of LaNeo™ MDMA to UCLA for Schizophrenia Study
- PharmAla to supply STRONG STAR at UT Health San Antonio, with novel dosage form of LaNeo™ MDMA
- PharmAla Signs Advisory Agreement with Mr. Matthew Azrieli
- PharmAla To Supply Merhavim Mental Health Centre Clinical Trial in Exchange for Full Data License, in Partnership with MAPS Israel
- PharmAla Issues Audited Financial Statements, Completes Continuance to Ontario, and Closes Private Placement
- PharmAla Announces Private Placement
- PharmAla Reaches Agreement in Principle to Supply MDMA to Clinical Trial in Exchange for Full Data License
- PharmAla to supply Mt. Sinai Hospital with LaNeo MDMA
- PharmAla to supply the University of Texas, San Antonio, with novel dosage form of LaNeo™ MDMA
- PharmAla to supply Harvard Medical School’s Maclean Hospital with LaNeo MDMA
- PharmAla to supply Johns Hopkins Medicine for Clinical Trial
- PharmAla Launches MDMA Clinical Trial Tool for Researchers
- PharmAla Comments on USFDA Decision regarding MDMA-Assisted Therapy and Announces Patent Granting for ALA-002
- PharmAla Provides Comprehensive Investor Update Following Release of Q3 Financial Statement
- Red Light Holland Announces Completion of Full Psilocybin Extraction Report with PharmAla
- Pharmala Biotech: CEO Letter To Shareholders
- Red Light Holland Initiates Psilocybin Extraction Phase with PharmAla Following Successful Testing and Preparation by CCrest Labs
- PharmAla CEO Nick Kadysh Pens Op-ed: Mental Health in Crisis, MDMA May Be the Prescription
- PharmAla Launches Prescriber’s Portal for Medical Professionals Focused on MDMA Therapy
- Red Light Holland Initiates Psilocybin Extraction Phase with PharmAla Following Successful Testing and Preparation by CCrest Labs
- PharmAla Closes Private Placement and Concurrent Debt Settlement
- PharmAla Announces Private Placement and Concurrent Debt Settlement
- Cortexa Commences Manufacturing GMP LaNeo™ MDMA in Australia
- Patent Allowance Granted for ALA-002 Composition by US Patent and Trademark Office
- PharmAla Biotech Signs Sale Agreement with Numinus
- PharmAla Biotech Holdings Inc. Announces Joint Venture with Cortexa Pty. Ltd
- PharmAla and Red Light Holland to Collaborate on Medical Psilocybin Development
- PharmAla releases Profitable Q1 Interim Financial Statement and Business Update
- PharmAla releases Profitable Q1 Interim Financial Statement and Business Update
- PharmAla granted a Controlled Drugs & Substances Dealer’s License by Health Canada.
- PharmAla receives new “MDXXF” ticker from FINRA for OTCQB Listing
Showing the 40 most recent of 76 articles.